MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 598795 | Name: MI 1544

Description:

WARNING: This product is for research use only, not for human or veterinary use.

MI 1544 is a LHRH antagonist.

Chemical Structure

MI 1544
MI 1544
CAS#87565-51-3

Theoretical Analysis

MedKoo Cat#: 598795

Name: MI 1544

CAS#: 87565-51-3

Chemical Formula: C71H94ClN17O13

Exact Mass: 1427.6906

Molecular Weight: 1429.08

Elemental Analysis: C, 59.67; H, 6.63; Cl, 2.48; N, 16.66; O, 14.55

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
MI 1544; MI-1544; MI1544; Attcpl-LHRH; Attcpl LHRH; AttcplLHRH;
IUPAC/Chemical Name
(S)-N-((R)-1-((R)-2-acetamido-3-(1H-indol-3-yl)propanamido)-1-oxopropan-2-yl)-1-(((R)-2-amino-3-(4-chlorophenyl)propanoyl)-D-tryptophyl-L-seryl-L-tyrosyl-D-lysyl-L-leucyl-L-arginyl)pyrrolidine-2-carboxamide
InChi Key
SJIRJOKZIDRUQX-ZIJAQKSWSA-N
InChi Code
1S/C71H94ClN17O13/c1-39(2)31-55(64(96)83-54(18-11-29-77-71(75)76)70(102)89-30-12-19-60(89)69(101)80-40(3)61(93)88-67(99)57(81-41(4)91)34-44-36-78-51-15-7-5-13-48(44)51)85-63(95)53(17-9-10-28-73)82-65(97)56(33-43-22-26-47(92)27-23-43)86-68(100)59(38-90)87-66(98)58(35-45-37-79-52-16-8-6-14-49(45)52)84-62(94)50(74)32-42-20-24-46(72)25-21-42/h5-8,13-16,20-27,36-37,39-40,50,53-60,78-79,90,92H,9-12,17-19,28-35,38,73-74H2,1-4H3,(H,80,101)(H,81,91)(H,82,97)(H,83,96)(H,84,94)(H,85,95)(H,86,100)(H,87,98)(H4,75,76,77)(H,88,93,99)/t40-,50-,53-,54+,55+,56+,57-,58-,59+,60+/m1/s1
SMILES Code
N[C@H](Cc1ccc(Cl)cc1)C(N[C@H](Cc(c[nH]2)c3c2cccc3)C(N[C@@H](CO)C(N[C@@H](Cc4ccc(O)cc4)C(N[C@H](CCCCN)C(N[C@@H](CC(C)C)C(N[C@@H](CCCNC(N)=N)C(N(CCC5)[C@@H]5C(N[C@H](C)C(NC([C@@H](Cc(c[nH]6)c7c6cccc7)NC(C)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 1,429.08 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Vincze B, Pályi I, Daubner D, Kálnay A, Mezö G, Hudecz F, Szekerke M, Teplán I, Mezö I. Antitumour effect of a gonadotropin-releasing-hormone antagonist (MI-1544) and its conjugate on human breast cancer cells and their xenografts. J Cancer Res Clin Oncol. 1994;120(10):578-84. PubMed PMID: 7929528. 2: Mezö G, Mezö I, Pimm MV, Kajtár J, Seprödi J, Teplán I, Kovács M, Vincze B, Pályi I, Idei M, Szekerke M, Hudecz F. Synthesis, conformation, biodistribution, and hormone-related in vitro antitumor activity of a gonadotropin-releasing hormone antagonist-branched polypeptide conjugate. Bioconjug Chem. 1996 Nov-Dec;7(6):642-50. PubMed PMID: 8950483. 3: Kovács M, Koppán M, Mezö I, Teplán I, Flerkó B. Antiovulatory doses of antagonists of LH-RH inhibit LH and progesterone but not FSH and estradiol release. J Neuroendocrinol. 1993 Dec;5(6):603-8. PubMed PMID: 8680431. 4: Pályi I, Vincze B, Lovas S, Mezö I, Pató J, Kálnay A, Turi G, Gaál D, Mihalik R, Péter I, Teplán I, Murphy RF. Gonadotropin-releasing hormone analogue conjugates with strong selective antitumor activity. Proc Natl Acad Sci U S A. 1999 Mar 2;96(5):2361-6. PubMed PMID: 10051647; PubMed Central PMCID: PMC26789. 5: Vincze B, Pályi I, Gaál D, Pató J, Móra M, Mezõ I, Teplán I, Seprõdi J. In vivo studies of the new gonadotropin-releasing hormone antagonist--copolymer conjugates having antitumor activity. Cancer Detect Prev. 1996;20(2):153-9. PubMed PMID: 8706041. 6: Kovacs M, Seprodi J, Koppan M, Horvath JE, Vincze B, Teplan I, Flerko B. Lamprey gonadotropin hormone-releasing hormone-III has no selective follicle-stimulating hormone-releasing effect in rats. J Neuroendocrinol. 2002 Aug;14(8):647-55. PubMed PMID: 12153467. 7: Pályi I, Vincze B, Kálnay A, Turi G, Mezõ I, Teplán I, Seprõdi J, Pató J, Móra M. Effect of gonadotropin-releasing hormone analogs and their conjugates on gonadotropin-releasing hormone receptor--positive human cancer cell lines. Cancer Detect Prev. 1996;20(2):146-52. PubMed PMID: 8706040. 8: Koppán M, Kovács M, Mezö I, Flerkó B. Electrochemical stimulation of the median eminence evokes FSH but not LH release after LHRH antagonist treatment in vivo and in vitro. J Neuroendocrinol. 1998 Mar;10(3):231-6. PubMed PMID: 9576611. 9: Chiu TH, Tsai SJ, Wu TY, Fu SC, Hwang YT. Improvement in antioxidant activity, angiotensin-converting enzyme inhibitory activity and in vitro cellular properties of fermented pepino milk by Lactobacillus strains containing the glutamate decarboxylase gene. J Sci Food Agric. 2013 Mar 15;93(4):859-66. doi: 10.1002/jsfa.5809. Epub 2012 Jul 20. PubMed PMID: 22821435. 10: Kovács M, Mezö I, Seprödi J, Csernus V, Teplán I, Flerkó B. Effects of long-term administration of a superactive agonistic and an antagonistic GnRH analog on the pituitary-gonad system. Peptides. 1989 Sep-Oct;10(5):925-31. PubMed PMID: 2691997. 11: Natsch A, Gfeller H, Emter R, Ellis G. Use of in vitro testing to identify an unexpected skin sensitizing impurity in a commercial product: a case study. Toxicol In Vitro. 2010 Mar;24(2):411-6. doi: 10.1016/j.tiv.2009.10.015. Epub 2009 Oct 31. PubMed PMID: 19883749. 12: Carlomagno F, Vitagliano D, Guida T, Napolitano M, Vecchio G, Fusco A, Gazit A, Levitzki A, Santoro M. The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes. Cancer Res. 2002 Feb 15;62(4):1077-82. PubMed PMID: 11861385. 13: Kovács M, Vincze B, Horváth JE, Seprodi J. Structure-activity study on the LH- and FSH-releasing and anticancer effects of gonadotropin-releasing hormone (GnRH)-III analogs. Peptides. 2007 Apr;28(4):821-9. Epub 2007 Jan 13. PubMed PMID: 17289216. 14: Kovács M, Koppán M, Mezó I, Teplán I. Diverse effects of a potent LH-RH antagonist on the LH and FSH release. Acta Biol Hung. 1994;45(2-4):285-96. PubMed PMID: 7725823. 15: Miller ME, Michaylira CZ, Simmons JG, Ney DM, Dahly EM, Heath JK, Lund PK. Suppressor of cytokine signaling-2: a growth hormone-inducible inhibitor of intestinal epithelial cell proliferation. Gastroenterology. 2004 Aug;127(2):570-81. PubMed PMID: 15300589. 16: Kovacs M, Mezo I, Flerko B, Teplan I, Nikolics K. Long-term inhibition of ovulation by a GnRH-antagonist at low dose level. Biochem Biophys Res Commun. 1984 Jan 13;118(1):351-5. PubMed PMID: 6365100.